150 related articles for article (PubMed ID: 33444574)
1. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B.
Cook L; Rees WD; Wong MQ; Peters H; Levings MK; Steiner TS
Gastroenterology; 2021 May; 160(6):2155-2158.e4. PubMed ID: 33444574
[No Abstract] [Full Text] [Related]
2. Recurrent Clostridioides difficile Infection Is Associated With Impaired T Helper Type 17 Immunity to C difficile Toxin B.
Cook L; Rees WD; Wong MQ; Kwok WW; Levings MK; Steiner TS
Gastroenterology; 2021 Mar; 160(4):1410-1413.e4. PubMed ID: 33253683
[No Abstract] [Full Text] [Related]
3. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
Wullt M; Norén T; Ljungh A; Åkerlund T
Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
[TBL] [Abstract][Full Text] [Related]
4. Fecal Microbiota Transplant for Clostridium difficile Infection in a Pregnant Patient.
Saeedi BJ; Morison DG; Kraft CS; Dhere T
Obstet Gynecol; 2017 Mar; 129(3):507-509. PubMed ID: 28178052
[TBL] [Abstract][Full Text] [Related]
5. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection.
Frisbee AL; Saleh MM; Young MK; Leslie JL; Simpson ME; Abhyankar MM; Cowardin CA; Ma JZ; Pramoonjago P; Turner SD; Liou AP; Buonomo EL; Petri WA
Nat Commun; 2019 Jun; 10(1):2712. PubMed ID: 31221971
[TBL] [Abstract][Full Text] [Related]
6. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.
Girotra M; Garg S; Anand R; Song Y; Dutta SK
Dig Dis Sci; 2016 Oct; 61(10):3007-3015. PubMed ID: 27447476
[TBL] [Abstract][Full Text] [Related]
7. The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection.
Rigo I; Young MK; Abhyankar MM; Xu F; Ramakrishnan G; Naz F; Madden GR; Petri WA
Anaerobe; 2024 Jun; 87():102842. PubMed ID: 38552897
[TBL] [Abstract][Full Text] [Related]
8. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
Núñez F P; Quera R; Bay C; Thomson P
Gastroenterol Hepatol; 2022 Mar; 45(3):223-230. PubMed ID: 34118321
[TBL] [Abstract][Full Text] [Related]
9. Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome.
Martínez-Ayala P; González-Hernández LA; Amador-Lara F; Andrade-Villanueva J; Ramos-Solano M
Rev Gastroenterol Mex (Engl Ed); 2019; 84(1):110-112. PubMed ID: 29449093
[No Abstract] [Full Text] [Related]
10. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.
Ryan ET; Butterton JR; Smith RN; Carroll PA; Crean TI; Calderwood SB
Infect Immun; 1997 Jul; 65(7):2941-9. PubMed ID: 9199470
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI.
Gerding DN; Johnson S
Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):67-8. PubMed ID: 21293502
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Clostridium difficile infection: an immunodeficiency state?
Pardi DS
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):672-3. PubMed ID: 17544993
[No Abstract] [Full Text] [Related]
13. Septic shock due to refractory severe clostridioides difficile colitis rapidly resolving after faecal microbiota transplantation.
Benech N; Leboucher G; Monard C; Ferry T
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32900719
[No Abstract] [Full Text] [Related]
14. Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT)
Garza-González E; Mendoza-Olazarán S; Morfin-Otero R; Ramírez-Fontes A; Rodríguez-Zulueta P; Flores-Treviño S; Bocanegra-Ibarias P; Maldonado-Garza H; Camacho-Ortiz A
Can J Gastroenterol Hepatol; 2019; 2019():4549298. PubMed ID: 31976311
[TBL] [Abstract][Full Text] [Related]
15. Rapid effect of fecal transplantation on C. difficile colitis.
Pérez-Alba E; Ortíz-Meza IA; Flores-Gutiérrez JP; Scharrer S; Alfaro-Rivera CG; Camacho-Ortiz A
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):e152-e153. PubMed ID: 32173308
[No Abstract] [Full Text] [Related]
16. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.
Warny M; Vaerman JP; Avesani V; Delmée M
Infect Immun; 1994 Feb; 62(2):384-9. PubMed ID: 8300199
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.
Salcedo J; Keates S; Pothoulakis C; Warny M; Castagliuolo I; LaMont JT; Kelly CP
Gut; 1997 Sep; 41(3):366-70. PubMed ID: 9378393
[TBL] [Abstract][Full Text] [Related]
18. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.
Johnson S; Gerding DN; Janoff EN
J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG.
Biller JA; Katz AJ; Flores AF; Buie TM; Gorbach SL
J Pediatr Gastroenterol Nutr; 1995 Aug; 21(2):224-6. PubMed ID: 7472911
[No Abstract] [Full Text] [Related]
20. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile.
Steele J; Sponseller J; Schmidt D; Cohen O; Tzipori S
Hum Vaccin Immunother; 2013 Jul; 9(7):1565-8. PubMed ID: 23435084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
